ABT-263, AT-101, and GX15–070 are common anti-apoptotic BCL2-family inhibitors, which are known to bind to specific p2 and p4 (p1 and p3 for AT-101) hydrophobic pockets of BCL-XL [44–46], whereas these compounds exhibited the diverse biological activities including different killing effects on cancer cells [44,45] and latently HIV-1-infected cells (Fig 2). Here, BCL2 is linked to cancer.